Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...

Over the past three decades, tremendous achievements have been made in the treatment of patients with multiple myeloma (MM), ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA's Oncologic Drugs Advisory Committee ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

But Tecvayli’s cancer target, BCMA, is already addressed by several multiple myeloma drugs, including the J&J and Legend Biotech CAR T-therapy Carvykti. To date, there are no FDA-approved drugs ...

Blenrep’s 2020 accelerated FDA approval covered the use of the drug as a fifth-line multiple myeloma therapy, making it the first approved BCMA-targeting therapy. But after the drug, tested as a ...

Patients with drug-resistant multiple myeloma find early success with a new CAR T therapy, a recent study finds . Newsletters Games Share a News Tip. Featured. Featured. Breaking News.

ATLANTA, Georgia — An investigational drug for multiple myeloma, the first oral proteasome inhibitor, has shown promising results in an early phase1/2 clinical trial and has progressed straight ...